(Press-News.org) The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition.
AFCR’s BRACE (Bridging Research from Academia to Cancer Entrepreneurship) Award Venture Competition is designed to support and accelerate oncology innovations on their path toward commercialization, with the ultimate goal of improving outcomes for patients affected by cancer globally. AFCR aims to support the winners of the BRACE Award with funding resources, advisory experts, and access to our global network of key opinion leaders in cancer research.
The winner of the BRACE Award Venture Competition must past the three-step rigorous evaluation process undertaken by the BRACE program's blue-ribbon Committees: Selection, Judging, and Investment.
Degron Therapeutics, headquartered in Shanghai and with labs in the US and China, is at the forefront of developing a novel class of small molecule drugs through its molecular glue-based targeted protein degradation platform.
Degron Therapeutics stands as a global leader in the discovery and development of a new class of small molecule drugs termed molecular glue degraders. Through their proprietary GlueXplorer platform, Degron Therapeutics has curated a unique and expanding library of molecular glue compounds, enabling the targeting of previously undruggable targets. This platform leverages phenotypic screening, proteomic screening, and artificial intelligence (AI) to predict novel targets and expedite compound discovery. Degron Therapeutics has rapidly expanded its proprietary glue chemical library, thereby identifying a growing list of potentially degradable disease targets. Among these, a novel degrader of a previously “undruggable” RNA-binding protein that regulates cancer survival and metastasis leads the way, showcasing impressive potency, selectivity, and preliminary pharmacokinetics.
The Committees of the BRACE Award Venture Competition recognize that Degron Therapeutic’s novel technology holds great promise in positively impacting patients as demonstrated by an investment of HK$2,300,000, as part of Degron Therapeutics’ upcoming Series A+ funding round.
“Novel approaches for inactivating important proteins that are critical for tumor maintenance are most welcome,” said BRACE Award Venture Competition Selection and Judging Committee Co-Chair Raju Kucherlapati, Ph.D. “The committee was impressed with their GlueXplorer platform which could potentially be a game-changer in identifying novel cancer targets that are previously undruggable.”
"We are elated to be honored with the prestigious title of the 2023 BRACE Award Venture Competition winner and express our deep gratitude for the support from AFCR. The invaluable connections forged with accomplished advisors are very beneficial to us," said Dr. Lily Zou, Co-Founder and CEO of Degron Therapeutics. "We are excited by the recognition and credibility that comes with this award and look forward to collaborating with AFCR as we strive to redefine cancer treatment not only in Asia but worldwide."
“As we enter the 4th year since the inauguration of the BRACE Award Venture Competition, we are proud to be recognized as a valuable source of impact investment for early-stage oncology companies,” expressed Asian Fund for Cancer Research President and CEO, Founder Sujuan Ba, Ph.D. “The competition continues to advocate and accelerate the development of innovative concepts from the bench to the bedside for cancer patients in Asia and the rest of the world.”
About the BRACE Award Venture Competition
The Bridging Research from Academia to Cancer Entrepreneurship (BRACE) Award program is designed to provide vital support to early-stage biotechs, enabling them to accelerate their innovative therapeutics, diagnostics, and cancer prevention products into the clinic, with the ultimate goal of improving outcomes for patients affected by cancer, globally. BRACE Award Venture Competitions provide start-up companies with investment capital, prize honorarium, exposure-generating opportunities and enhanced access to a network of cancer industry leaders and researchers in the region and around the world. Three committees (Selection, Pitch Judging and Investment), whose members are world-class key opinion leaders, life sciences industry experts, investors and entrepreneurs, provide assessments and recommendations for the investment from AFCR. the 2023 Committee members include the following persons:
Anna D. Barker, Ph.D., Chief Strategy Officer, Ellison Institute for Transformative Medicine
Webster K. Cavenee, Ph.D., Distinguished Professor Emeritus, University of California San Diego
Yijing (Jane) Chen, Ph.D., Associate, Wilson Sonsini Goodrich & Rosati
Aleksandra Filipovic, M.D., Ph.D., Head of Oncology, PureTech Health
Pamela Garzone, Ph.D., Chief Development Officer, Anixa Biosciences
Dimitra Georganopoulou, Ph.D., Innovation – Investment | General Partner, Qral Ventures
Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
Brian Leyland-Jones, MBBS, Ph.D., Chief Medical Officer, National Foundation for Cancer Research
Scott Lippman, M.D., Distinguished Professor of Medicine & Associate Vice Chancellor for Cancer Research, University of California San Diego Health
Beverly Lu, Ph.D., Investment Manager, Health, Emerson Collective
Jimmy Lu, J.D., MBA, Co-Founder & Managing Director, Eos BioInnovation
Eva Martin, M.D., Senior Director, Alliance and Asset Management, Roche Pharma Partnering
Tom Miller, Founder & Managing Partner, GreyBird Ventures
Gregory W. Mitchell, Ph.D., J.D., Counsel, Wilson Sonsini Goodrich & Rosati
Kornelia Polyak, M.D., Ph.D., Professor of Medicine, Dana-Farber Cancer Institute
Fei Shen, Ph.D., Managing Director, Boehringer Ingelheim Venture Fund USA
Suzanne Topalian, M.D., Associate Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Kevin Tylock, Ph.D., J.D., Associate, Wilson Sonsini Goodrich & Rosati
Learn more about the BRACE Award Venture Competition at https://AFCR.org/en/Brace-Award/.
About the Asian Fund for Cancer Research
The Asian Fund for Cancer Research (AFCR) is a nonprofit organization committed to combatting cancers that disproportionately affect Asian populations. Headquartered in Hong Kong and with a global reach, AFCR is uniquely positioned to investigate the unique causes of cancer in Asian demographics through innovative genetic and molecular research. The organization accelerates cutting-edge cancer research breakthroughs and technologies while developing more potent therapies for cancer patients across Asia and the world. Further information about AFCR can be found at https://afcr.org.
About Degron Therapeutics
Degron Therapeutics, established in April 2021, is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening system to develop a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of preclinical compounds for oncology, inflammation, metabolic disease, and rare diseases. For more information, please visit www.degrontx.com.
END
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
2023-12-28
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Social media platforms generate billions in annual ad revenue from US youth
2023-12-27
Embargoed for release: December 27, 2023, 2:00 PM ET
Key points:
Researchers estimated that Facebook, Instagram, Snapchat, TikTok, X (formerly Twitter), and YouTube collectively derived nearly $11 billion in advertising revenue during 2022 from U.S. youth, who are vulnerable to negative mental health outcomes.
The study is the first to offer estimates of the number of youth users on these platforms and how much annual ad revenue is attributable to them.
According to the researchers, the study’s ...
Virtual care works best when patients see their own family doctor, study finds
2023-12-27
Toronto, ON, December 27, 2023 – Compared to patients who had a virtual visit with their own family doctor, those who received virtual care from a doctor outside of their family care team were 66 percent more likely to visit the emergency department within seven days, according to new research.
The study, led by researchers at the University Health Network (UHN), Unity Health Toronto, and ICES, also showed that patients receiving virtual care outside of an existing family doctor-patient relationship were 25 percent more likely to have an in-person visit and 88 percent more likely to have another virtual visit within seven days.
“This study sheds light on how different types ...
Consistency and accuracy of AI for providing nutritional information
2023-12-27
About The Study: The results of this study suggest that artificial intelligence (AI) can be a useful and convenient tool for people who want to know the energy and macronutrient information of their foods. Although AI chatbots cannot replace nutritionists, they may provide real-time analysis of foods, and the capacity to harness AI technology in a supportive role may fundamentally transform the way nutritionists communicate with patients.
Authors: Jung-Su Chang, Ph.D., of Taipei Medical University in Taipei, Taiwan, is the corresponding author.
To ...
Low-carbohydrate diet macronutrient quality and weight change
2023-12-27
About The Study: In this study using data from three large prospective cohort studies among 123,000 individuals, low-carbohydrate diets that emphasized high-quality proteins, fats and carbohydrates from whole grains and other healthy plant-based foods were significantly associated with slower weight gain in the long term. In contrast, low-carbohydrate diets emphasizing animal-sourced proteins and fats or refined carbohydrates were associated with faster weight gain.
Authors: Qi Sun, M.D., Sc.D., of the Harvard T.H. Chan School of Public Health in Boston, is the corresponding author.
To access the ...
Benzodiazepine use during pregnancy and risk of miscarriage
2023-12-27
About The Study: This nationwide case-time-control study revealed an increased risk of miscarriage associated with benzodiazepine use during pregnancy after accounting for measurable confounders, and results were unlikely to be due to unmeasured confounding. These findings underscore the necessity for health care professionals to meticulously balance the risk-benefit ratio when considering the use of benzodiazepines to treat psychiatric and sleep disorders during pregnancy.
Authors: Fei-Yuan Hsiao, Ph.D., of National ...
Comparison of capture rates of the National Cancer Database across race and ethnicity
2023-12-27
About The Study: In this study of individuals diagnosed with cancer in the National Cancer Database (NCDB), Hispanic and American Indian or Alaska Native individuals diagnosed with breast, colorectal, lung, and prostate cancer were undercaptured in the NCDB, but their representation improved over time. Increased study is needed to determine where these populations predominantly seek cancer care.
Authors: Juan Javier-DesLoges, M.D., M.S., of the University of California, San Diego, is the corresponding author.
To ...
A study of the genetics of pericarditis increases understanding of newly approved drug treatment
2023-12-27
A study of the genetics of pericarditis increases understanding of newly approved drug treatment
Sequence variants that protect against pericarditis have been discovered at a genomic locus encoding interleukin-1 immune cytokines. A newly approved drug treatment for pericarditis inhibits these cytokines and new a study from deCODE genetics and collaborators can contribute to the further development of this treatment.
A new study called “Variants at the interleukin-1 gene locus and pericarditis” was published today in the journal JAMA Cardiology, by scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Denmark, USA, and Iceland.
The study involves ...
New reptile on the block: A new iguana species discovered in China
2023-12-27
A new iguana joins Asia’s rich reptile fauna, officially described as new to science in the open-access journal ZooKeys.
“From 2009 to 2022, we conducted a series of field surveys in South China and collected a number of specimens of the Calotes versicolor species complex, and found that the population of what we thought was Calotes versicolor in South China and Northern Vietnam was a new undescribed species and two subspecies,” says Yong Huang, whose team described the new species.
Wang’s garden ...
Quality of care declines after private equity takes over hospitals
2023-12-26
At a glance:
National study of quality of care in hospitals acquired by private equity shows worsening of fall and infection risk, other measures of quality and safety.
Some post-procedure adverse events increased even though private equity hospitals performed fewer procedures among younger and less disadvantaged patients.
The new findings amplify existing economic concerns about the growth of this for-profit ownership model.
Patients are more likely to fall, get new infections, or experience other forms of harm during their stay in a hospital after it is acquired by a private equity firm, according to a new ...
Changes in hospital adverse events and patient outcomes associated with private equity acquisition
2023-12-26
About The Study: Private equity acquisition of hospitals, on average, was associated with increased hospital-acquired adverse events despite a likely lower-risk pool of admitted Medicare beneficiaries, suggesting poorer quality of inpatient care. These findings heighten concerns about the implications of private equity on health care delivery.
Authors: Zirui Song, M.D., Ph.D., of Harvard Medical School in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.23147)
Editor’s Note: Please see the article for additional ...